Tuesday, September 29, 2020 8:04:58 AM
Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover
09/15/2020 3,704,007 2.20 396,560 9.34
08/31/2020 3,624,255 31.32 554,074 6.54
08/14/2020 2,759,900 (4.90) 201,768 13.68
07/31/2020 2,901,991 (1.32) 164,265 17.67
07/15/2020 2,940,745 (7.83) 261,889 11.23
06/30/2020 3,190,583 13.89 444,310 7.18
06/15/2020 2,801,353 (1.75) 283,038 9.90
05/29/2020 2,851,334 2.43 353,974 8.06
05/15/2020 2,783,765 2.57 328,963 8.46
04/30/2020 2,713,943 (4.19) 342,958 7.91
04/15/2020 2,832,539 19.36 231,033 12.26
03/31/2020 2,373,139 (5.19) 199,335 11.91
03/13/2020 2,502,936 7.87 354,033 7.07
02/28/2020 2,320,223 (4.81) 159,130 14.58
02/14/2020 2,437,464 (2.04) 134,058 18.18
01/31/2020 2,488,238 (0.12) 232,741 10.69
01/15/2020 2,491,195 6.48 292,650 8.51
12/31/2019 2,339,563 30.02 1,174,529 1.99
12/13/2019 1,799,433 (2.99) 182,069 9.88
11/29/2019 1,854,966 (15.81) 240,531 7.71
11/15/2019 2,203,310 (14.78) 323,602 6.81
10/31/2019 2,585,569 8.59 530,616 4.87
10/15/2019 2,381,117 3.45 138,734 17.16
09/30/2019 2,301,761 (1.62) 128,398 17.9
Recent SYRS News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 09:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 11:01:02 AM
- Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences • Business Wire • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 09:03:51 PM
- Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial • Business Wire • 08/12/2024 08:15:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/02/2024 10:39:25 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/31/2024 11:44:08 AM
- Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update • Business Wire • 07/31/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 10:55:07 AM
- Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 • Business Wire • 07/24/2024 11:00:00 AM
- Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression • Business Wire • 06/13/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:30:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:30:54 PM
- Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update • Business Wire • 05/14/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 10:42:01 AM
- Syros to Participate in Upcoming Investor Conferences • Business Wire • 05/07/2024 01:00:00 PM
- Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 • Business Wire • 05/07/2024 11:00:00 AM
- Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression • Business Wire • 04/09/2024 11:00:00 AM
- Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/02/2024 08:30:00 PM
- Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update • Business Wire • 03/27/2024 11:30:00 AM
- U.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early Trading • IH Market News • 03/27/2024 10:57:08 AM
- Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial • Business Wire • 03/25/2024 11:00:00 AM
- Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024 • Business Wire • 03/20/2024 11:00:00 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM